Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB3290 |
Synonyms | |
Therapy Description |
BGB3290 inhibits RAF dimer formation, which may lead to inhibition of Erk signaling and cell growth (PMID: 29880583). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB3290 | BGB-3290|BGB 3290 | BGB3290 inhibits RAF dimer formation, which may lead to inhibition of Erk signaling and cell growth (PMID: 29880583). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF L514V BRAF V600E | melanoma | predicted - sensitive | BGB3290 | Preclinical - Cell culture | Actionable | In a preclinical study, BGB3290 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583). | 29880583 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|